Oportuzumab monatox

Explore a selection of our essential drug information below, or:

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Overview

DrugBank ID: DB05319
Type: Biotech
US Approved: NO
Other Approved: NO
Patents: 0
Indicated Conditions: 0
Clinical Trials: Phase 0
0
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0

Identification

Generic Name

Oportuzumab monatox

DrugBank Accession Number

DB05319

Background

VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A.

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies
Other protein based therapies

Protein Chemical Formula

Not Available

Protein Average Weight

Not Available

Sequences

>9045_H|oportuzumab monatox|||SCFV-KAPPA-HEAVY-TOXIN (V-KAPPA(7-118)+LINKER(119-144)+VH(145-260)+TOX-DOMAIN(281-637))|||||||647||||MW 69566.3|MW 69566.3|
HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIY
QMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRA
TPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNW
VKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYC
ARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLET
FTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIRE
QPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLE
RNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIV
FGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGF
YRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAI
PTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL

Download FASTA Format

Synonyms

Oportuzumab monatox

External IDs

VB4-845

Get Early Access To DrugBank+

Be among the first to try our new AI-powered, game-changing platform. DrugBank+ is here to streamline your pharmaceutical research and deliver faster insights and smarter decisions.

Join the Waitlist

Get Early Access To DrugBank+

Join the Waitlist

Pharmacology

Indication

Investigated for use/treatment in bladder cancer and head and neck cancer.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

VB4-845 binds to EpCAM (a protein on the surface of epithelial cells and some types of cancer cells). Also called anti-EpCAM-Pseudomonas-exotoxin fusion protein and Proxinium. It targets and kills Ep-CAM-positive tumors by apoptosis.

Target	Actions	Organism
UEpithelial cell adhesion molecule	Not Available	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Unlock the secrets to drugging the undruggable

Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.

Download eBook

Unlock the secrets to drugging the undruggable

Download eBook

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Products

: Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands: Proxinium / Vicinium

Chemical Identifiers

UNII: 945CY7ZMI2
CAS number: 945228-48-8

References

General References

Not Available

External Links

PubChem Substance: 347910078
Wikipedia: Oportuzumab_monatox

Clinical Trials

Clinical Trials Clinical Trial & Rare Diseases Add-on Data Package Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
3	Completed	Treatment	Bladder Cancer	1	somestatus	stop reason	just information to hide
3	Unknown Status	Treatment	Non-Muscle-invasive Bladder Cancer (NMIBC)	1	somestatus	stop reason	just information to hide
2	Completed	Treatment	Bladder Cancer / Bladder Neoplasm	1	somestatus	stop reason	just information to hide
2	Terminated	Treatment	Head And Neck Cancer / Head and Neck Neoplasms / Mouth Neoplasms / Neoplasms, Squamous Cell / Squamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1	somestatus	stop reason	just information to hide
2, 3	Terminated	Treatment	Head And Neck Cancer / Head and Neck Neoplasms / Mouth Neoplasms / Neoplasms, Squamous Cell / Squamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)	1	somestatus	stop reason	just information to hide

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Solid
Experimental Properties: Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Epithelial cell adhesion molecule

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E
Specific Function: cadherin binding involved in cell-cell adhesion
Gene Name: EPCAM
Uniprot ID: P16422
Uniprot Name: Epithelial cell adhesion molecule
Molecular Weight: 34932.005 Da

Drug created at November 18, 2007 18:23 / Updated at January 14, 2023 19:04

Oportuzumab monatox

Overview

Identification

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Pharmacoeconomics

Properties

Targets